GeneMind Raises Nearly RMB 400M in Series C Funding Round
GeneMind has raised nearly RMB 400 million in a Series C funding round, which it will put toward expanding the research and development of its products and applications, broadening the
Previous
Next
About us
From the company’s inception, GeneMind aimed at the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostics. Genemind is committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions.
Our Products
Our Technology
- 01
High sensitivity sequencing optical system
- Two-color / four-color optics, ultra-high sensitivity, capture of DNA’s dim signals
- High stability and reliability, effective resistance toward ambient temperature fluctuations and vibration interference
- 02
High-fidelity synthetic sequencing chemical system
- Unique terminator nucleotide structure, Highly efficient SBS (synthesis while sequencing) reaction
- Research and production capability of high-fidelity polymerase mutants
- 03
High-density sequencing chip
- High density, low noise surface chemical modification
- Surface probe / primer can be customized according to the application
- 04
Fast algorithm based on AI Machine learning
- Raw data-> AI Machine learning-> Basecall algorithm
- Application-oriented database and bioinformatics software
Application
NON-INVASIVE PRENATAL TESTING (NIPT)
PREIMPLANTATION GENETIC SCREENING (PGS)
Whole Exome Sequencing (WES)
News
FASTASeq300 Sequencing Platform GRAND LAUNCH
On November 28, GeneMind officially launched the third self-developed sequencing system FASTASeq 300. GeneMind showcased the instrument at Medlab Middle East 2023, making its first worldwide debut at booth Z1.B39,
GeneMind Launches New Site in Nanjing to build a business presence in Yangtze River Delta Region
On March, GeneMind and Nanjing Jiangbei New District have reached a strategic partnership. The cooperation mainly focuses on promoting the industrialization and development of high-throughput sequencing technology. The two parties
